ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Other Working Capital Changes of -$61000.0 for Q1 2026, down 10.91% sequentially from -$55000.0 in Q4 2025, and up 70.95% YoY from -$35682.5 in Q1 2025.
ARS Pharmaceuticals (SPRY) Other Working Capital Changes (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Other Working Capital Changes for 5 years, with the latest figure at -$61000.0 in Q1 2026.
- Quarterly Other Working Capital Changes rose 70.95% year-over-year to -$61000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$201000.0 (down 110.7% YoY) and the FY2025 annual result came in at -$350000.0, down 116.75% from the prior year.
- Other Working Capital Changes eased to -$61000.0 in Q1 2026 per SPRY's latest filing, from -$55000.0 in the prior quarter.
- Over five years, Other Working Capital Changes peaked at $7.3 million in Q4 2024 and troughed at -$4.1 million in Q2 2025.
- A 5-year average of $510588.2 and a median of -$92000.0 in 2022 frame the typical range for Other Working Capital Changes.
- The widest YoY moves for Other Working Capital Changes: up 97.84% in 2023, down 371.64% in 2023.
- Over 5 years, Other Working Capital Changes stood at -$189000.0 in 2022, then surged by 94.71% to -$10000.0 in 2023, then soared by 20990.0% to $2.1 million in 2024, then sank by 102.63% to -$55000.0 in 2025, then slipped by 10.91% to -$61000.0 in 2026.
- According to Business Quant data, Other Working Capital Changes over the past three periods registered -$61000.0, -$55000.0, and -$55000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.71 Mn |
| Jun 30, 2026 | 2.71 Mn |
| Jun 30, 2026 | 2.71 Mn |
| Mar 31, 2026 | 524,000.00 |
| Mar 31, 2026 | 524,000.00 |
| Mar 31, 2026 | 524,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Dec 31, 2025 | -284,000.00 |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Mar 31, 2025 | 4.80 Mn |
| Dec 31, 2024 | 7.25 Mn |
| Dec 31, 2024 | 7.25 Mn |